A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

NCT03918278 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

BIOLOGICAL: MK-0482
BIOLOGICAL: pembrolizumab
DRUG: Paclitaxel
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Merck Sharp & Dohme LLC